BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 30110638)

  • 1. Antibody Repertoires to the Same Ebola Vaccine Antigen Are Differentially Affected by Vaccine Vectors.
    Meyer M; Yoshida A; Ramanathan P; Saphire EO; Collins PL; Crowe JE; Samal S; Bukreyev A
    Cell Rep; 2018 Aug; 24(7):1816-1829. PubMed ID: 30110638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.
    Kimble JB; Malherbe DC; Meyer M; Gunn BM; Karim MM; Ilinykh PA; Iampietro M; Mohamed KS; Negi S; Gilchuk P; Huang K; Wolf YI; Braun W; Crowe JE; Alter G; Bukreyev A
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30518655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.
    Konduru K; Shurtleff AC; Bradfute SB; Nakamura S; Bavari S; Kaplan G
    PLoS One; 2016; 11(9):e0162446. PubMed ID: 27622456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP Administered Intranasally Is Immunogenic in African Green Monkeys.
    Lingemann M; Liu X; Surman S; Liang B; Herbert R; Hackenberg AD; Buchholz UJ; Collins PL; Munir S
    J Virol; 2017 May; 91(10):. PubMed ID: 28250127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus.
    Audet J; Wong G; Wang H; Lu G; Gao GF; Kobinger G; Qiu X
    Sci Rep; 2014 Nov; 4():6881. PubMed ID: 25375093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A heterologous prime-boost Ebola virus vaccine regimen induces durable neutralizing antibody response and prevents Ebola virus-like particle entry in mice.
    Chen T; Li D; Song Y; Yang X; Liu Q; Jin X; Zhou D; Huang Z
    Antiviral Res; 2017 Sep; 145():54-59. PubMed ID: 28733113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines.
    Dowling W; Thompson E; Badger C; Mellquist JL; Garrison AR; Smith JM; Paragas J; Hogan RJ; Schmaljohn C
    J Virol; 2007 Feb; 81(4):1821-37. PubMed ID: 17151111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors.
    Kuzmina NA; Younan P; Gilchuk P; Santos RI; Flyak AI; Ilinykh PA; Huang K; Lubaki NM; Ramanathan P; Crowe JE; Bukreyev A
    Cell Rep; 2018 Aug; 24(7):1802-1815.e5. PubMed ID: 30110637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-protection conferred by filovirus virus-like particles containing trimeric hybrid glycoprotein.
    Martins K; Carra JH; Cooper CL; Kwilas SA; Robinson CG; Shurtleff AC; Schokman RD; Kuehl KA; Wells JB; Steffens JT; van Tongeren SA; Hooper JW; Bavari S
    Viral Immunol; 2015 Feb; 28(1):62-70. PubMed ID: 25514232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal Human Antibody Repertoire against Complete Viral Proteome from Ebola Virus Survivor Reveals Protective Sites for Vaccine Design.
    Khurana S; Ravichandran S; Hahn M; Coyle EM; Stonier SW; Zak SE; Kindrachuk J; Davey RT; Dye JM; Chertow DS
    Cell Host Microbe; 2020 Feb; 27(2):262-276.e4. PubMed ID: 32053790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlates of vaccine-induced protective immunity against Ebola virus disease.
    Medaglini D; Santoro F; Siegrist CA
    Semin Immunol; 2018 Oct; 39():65-72. PubMed ID: 30041831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
    Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
    J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
    Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for EBOLA virus in guinea pigs.
    Mellquist-Riemenschneider JL; Garrison AR; Geisbert JB; Saikh KU; Heidebrink KD; Jahrling PB; Ulrich RG; Schmaljohn CS
    Virus Res; 2003 Apr; 92(2):187-93. PubMed ID: 12686428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ebola vaccine-induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects.
    Meyer M; Gunn BM; Malherbe DC; Gangavarapu K; Yoshida A; Pietzsch C; Kuzmina NA; Saphire EO; Collins PL; Crowe JE; Zhu JJ; Suchard MA; Brining DL; Mire CE; Cross RW; Geisbert JB; Samal SK; Andersen KG; Alter G; Geisbert TW; Bukreyev A
    Sci Transl Med; 2021 Jul; 13(602):. PubMed ID: 34261800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.
    Bengtsson KL; Song H; Stertman L; Liu Y; Flyer DC; Massare MJ; Xu RH; Zhou B; Lu H; Kwilas SA; Hahn TJ; Kpamegan E; Hooper J; Carrion R; Glenn G; Smith G
    Vaccine; 2016 Apr; 34(16):1927-35. PubMed ID: 26921779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epitope mapping of Ebola virus dominant and subdominant glycoprotein epitopes facilitates construction of an epitope-based DNA vaccine able to focus the antibody response in mice.
    Mitchell DAJ; Dupuy LC; Sanchez-Lockhart M; Palacios G; Back JW; Shimanovskaya K; Chaudhury S; Ripoll DR; Wallqvist A; Schmaljohn CS
    Hum Vaccin Immunother; 2017 Dec; 13(12):2883-2893. PubMed ID: 28699812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response.
    DiNapoli JM; Yang L; Samal SK; Murphy BR; Collins PL; Bukreyev A
    Vaccine; 2010 Dec; 29(1):17-25. PubMed ID: 21034822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques.
    Singh K; Marasini B; Chen X; Ding L; Wang JJ; Xiao P; Villinger F; Spearman P
    J Virol; 2020 Apr; 94(9):. PubMed ID: 32075939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Gamma Irradiation of Human Serum Samples from rVSVΔG-ZEBOV-GP (V920) Ebola Virus Vaccine Recipients on Plaque-Reduction Neutralization Assays.
    Grant-Klein RJ; Antonello J; Nichols R; Dubey S; Simon JK
    Am J Trop Med Hyg; 2021 Mar; 104(5):1751-1754. PubMed ID: 33782211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.